363 related articles for article (PubMed ID: 28619014)
41. Spider angiomas in patients with liver cirrhosis: role of vascular endothelial growth factor and basic fibroblast growth factor.
Li CP; Lee FY; Hwang SJ; Lu RH; Lee WP; Chao Y; Wang SS; Chang FY; Whang-Peng J; Lee SD
World J Gastroenterol; 2003 Dec; 9(12):2832-5. PubMed ID: 14669345
[TBL] [Abstract][Full Text] [Related]
42. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms.
Sasaki H; Yukiue H; Kobayashi Y; Nakashima Y; Moriyama S; Kaji M; Kiriyama M; Fukai I; Yamakawa Y; Fujii Y
Surg Today; 2001; 31(11):1038-40. PubMed ID: 11766079
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients.
Salven P; Orpana A; Teerenhovi L; Joensuu H
Blood; 2000 Dec; 96(12):3712-8. PubMed ID: 11090051
[TBL] [Abstract][Full Text] [Related]
44. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology.
Keyes KA; Mann L; Cox K; Treadway P; Iversen P; Chen YF; Teicher BA
Cancer Chemother Pharmacol; 2003 Apr; 51(4):321-7. PubMed ID: 12721760
[TBL] [Abstract][Full Text] [Related]
45. Angiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumors.
Peles E; Lidar Z; Simon AJ; Grossman R; Nass D; Ram Z
Neurosurgery; 2004 Sep; 55(3):562-7; discussion 567-8. PubMed ID: 15335423
[TBL] [Abstract][Full Text] [Related]
46. Clinical predictive value of serum angiogenic factor in patients with osteosarcoma.
Chen Z; Chen QX; Hou ZY; Hu J; Cao YG
Asian Pac J Cancer Prev; 2012; 13(9):4823-6. PubMed ID: 23167426
[TBL] [Abstract][Full Text] [Related]
47. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
48. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma.
Reddick WE; Wang S; Xiong X; Glass JO; Wu S; Kaste SC; Pratt CB; Meyer WH; Fletcher BD
Cancer; 2001 Jun; 91(12):2230-7. PubMed ID: 11413510
[TBL] [Abstract][Full Text] [Related]
49. [Expression of hypoxia-inducible factor 1α in osteosarcoma and its value in predicting chemosensitivity].
Chen Y; Wang CM; Shi YQ; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):899-904. PubMed ID: 23336375
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
51. Serum CEACAM1 Level Is Associated with Diagnosis and Prognosis in Patients with Osteosarcoma.
Yu H; Yu J; Ren Y; Yang Y; Xiao X
PLoS One; 2016; 11(4):e0153601. PubMed ID: 27074014
[TBL] [Abstract][Full Text] [Related]
52. [Assessment of angiogenesis in children' s osteosarcoma].
Sznurkowska K; Lenckowski R; Popadiuk S; Szumera M; Renke J; Korzon M
Med Wieku Rozwoj; 2006; 10(3 Pt 1):737-44. PubMed ID: 17317904
[TBL] [Abstract][Full Text] [Related]
53. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
54. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
55. Prognostic relevance of serum levels of the angiogenic peptide bFGF in advanced carcinoma of the head and neck treated by primary radiochemotherapy.
Dietz A; Rudat V; Conradt C; Weidauer H; Ho A; Moehler T
Head Neck; 2000 Oct; 22(7):666-73. PubMed ID: 11002321
[TBL] [Abstract][Full Text] [Related]
56. Presentation and Long-term Outcome of High-grade Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Díaz R; Salom M; Baixauli F; Gómez J; Llavador M; Castel V
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e272-7. PubMed ID: 25374283
[TBL] [Abstract][Full Text] [Related]
57. Angiogenic and coagulation-fibrinolysis factors in non Hodgkin's lymphoma.
Wróbel T; Poreba M; Mazur G; Poreba R; Pyszel A; Beck B; Steinmetz-Beck A; Andrzejak R; Kuliczkowski K
Neoplasma; 2006; 53(3):253-8. PubMed ID: 16652197
[TBL] [Abstract][Full Text] [Related]
58. ctDNA quantification improves estimation of outcomes in patients with high-grade osteosarcoma: a translational study from the OS2006 trial.
Audinot B; Drubay D; Gaspar N; Mohr A; Cordero C; Marec-Bérard P; Lervat C; Piperno-Neumann S; Jimenez M; Mansuy L; Castex MP; Revon-Riviere G; Marie-Cardine A; Berger C; Piguet C; Massau K; Job B; Moquin-Beaudry G; Le Deley MC; Tabone MD; Berlanga P; Brugières L; Crompton BD; Marchais A; Abbou S
Ann Oncol; 2024 Jun; 35(6):559-568. PubMed ID: 38142939
[TBL] [Abstract][Full Text] [Related]
59. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
[TBL] [Abstract][Full Text] [Related]
60. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
